Metabolic therapy with Sodium R lipoate plus hydroxycitrate: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
No edit summary |
(Updated category= to treatment_category= in TreatmentInfo template) |
||
| Line 9: | Line 9: | ||
|usefulness_rating=3 | |usefulness_rating=3 | ||
|notes=This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety. | |notes=This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety. | ||
| | |treatment_category=Over-the-Counter Drugs and Supplements | ||
|links= | |links= | ||
|toxicity_level=2 | |toxicity_level=2 | ||
|toxicity_explanation=The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects. | |toxicity_explanation=The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects. | ||
}} | }} | ||
Latest revision as of 10:27, 12 November 2024
| Property | Information |
|---|---|
| Drug Name | Sodium R Lipoate and Hydroxycitrate (METABLOC) |
| FDA Approval | No (Used in investigational metabolic therapy for brain tumors) |
| Used for | Investigational use in brain tumor treatment, including primary and metastatic gliomas |
| Clinical Trial Phase | Early clinical evaluation in a small case series |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Not specified in the provided information |
| OS without | Not specified |
| OS with | Varies; one GBM patient had a significant tumor shrinkage, others showed extended progression-free survival, including one patient surviving 87 months post-diagnosis |
| PFS without | Not specified |
| PFS with | Majority of newly diagnosed patients without disease progression for periods extending to 2-3 years, and in one case, 87 months |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2 |
| Toxicity Explanation | The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects. |
Notes: This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety.
From Ben Williams Book: Not specified
Loading comments...
